JP2013067645A5 - - Google Patents

Download PDF

Info

Publication number
JP2013067645A5
JP2013067645A5 JP2012272352A JP2012272352A JP2013067645A5 JP 2013067645 A5 JP2013067645 A5 JP 2013067645A5 JP 2012272352 A JP2012272352 A JP 2012272352A JP 2012272352 A JP2012272352 A JP 2012272352A JP 2013067645 A5 JP2013067645 A5 JP 2013067645A5
Authority
JP
Japan
Prior art keywords
administered
dose
body weight
maintenance
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012272352A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013067645A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2013067645A publication Critical patent/JP2013067645A/ja
Publication of JP2013067645A5 publication Critical patent/JP2013067645A5/ja
Pending legal-status Critical Current

Links

JP2012272352A 2006-02-09 2012-12-13 転移性乳癌の治療 Pending JP2013067645A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US77242106P 2006-02-09 2006-02-09
US60/772,421 2006-02-09
EP06002680 2006-02-09
EP06002680.4 2006-02-09

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2008553685A Division JP2009526770A (ja) 2006-02-09 2007-02-09 転移性乳癌の治療

Publications (2)

Publication Number Publication Date
JP2013067645A JP2013067645A (ja) 2013-04-18
JP2013067645A5 true JP2013067645A5 (enExample) 2014-02-06

Family

ID=38110762

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008553685A Pending JP2009526770A (ja) 2006-02-09 2007-02-09 転移性乳癌の治療
JP2012272352A Pending JP2013067645A (ja) 2006-02-09 2012-12-13 転移性乳癌の治療

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2008553685A Pending JP2009526770A (ja) 2006-02-09 2007-02-09 転移性乳癌の治療

Country Status (9)

Country Link
US (3) US7976842B2 (enExample)
EP (1) EP1981539B1 (enExample)
JP (2) JP2009526770A (enExample)
KR (1) KR101296264B1 (enExample)
AU (1) AU2007213920B2 (enExample)
CA (1) CA2638040A1 (enExample)
IL (1) IL192944A0 (enExample)
RU (1) RU2434640C2 (enExample)
WO (1) WO2007090670A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
US8921102B2 (en) 2005-07-29 2014-12-30 Gpb Scientific, Llc Devices and methods for enrichment and alteration of circulating tumor cells and other particles
KR101296264B1 (ko) * 2006-02-09 2013-08-14 암젠 리서치 (뮌헨) 게엠베하 전이성 유방암의 치료
US8372584B2 (en) 2006-06-14 2013-02-12 The General Hospital Corporation Rare cell analysis using sample splitting and DNA tags
EP2029779A4 (en) 2006-06-14 2010-01-20 Living Microsystems Inc HIGHLY PARALLEL SNP GENOTYPING UTILIZATION FOR FETAL DIAGNOSIS
US8137912B2 (en) 2006-06-14 2012-03-20 The General Hospital Corporation Methods for the diagnosis of fetal abnormalities
US20080050739A1 (en) 2006-06-14 2008-02-28 Roland Stoughton Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats
DE102006035617A1 (de) * 2006-07-31 2008-02-21 Siemens Ag Automatische Bestimmung von Tumorlast
US9623021B2 (en) * 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
EP2106212B1 (en) * 2007-01-22 2014-04-02 GTX, Inc. Nuclear receptor binding agents
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
JP5130999B2 (ja) * 2008-03-31 2013-01-30 住友ベークライト株式会社 抗癌剤の有効性予測方法
SMT201700149T1 (it) 2008-09-20 2017-05-08 Univ Leland Stanford Junior Diagnosi non invasiva di aneuploidia fetale mediante sequenziamento
US20130202625A1 (en) * 2010-01-21 2013-08-08 The Regents Of The University Of Californa Use of human erythrocytes for prevention and treatment of cancer dissemination and growth
CA2820384A1 (en) * 2010-12-06 2012-06-14 Cure Cancer Worldwide Corporation Methods of metabolic targeting cancer cells using chemo- and immunotherapy for treating cancer
WO2012158818A2 (en) * 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
FR2977674B1 (fr) * 2011-07-06 2015-08-14 Cisbio Bioassays Methode amelioree de detection et/ou de quantification d'un analyte present a la surface d'une cellule
MX2014002289A (es) 2011-08-26 2015-03-20 Merrimack Pharmaceuticals Inc Anticuerpos fc especificos en tandem.
US20130179184A1 (en) * 2012-01-06 2013-07-11 Katherine L. Hurst Individualized Dosing Technique With Multiple Variables
WO2013142390A1 (en) * 2012-03-21 2013-09-26 Gtx, Inc. Aldo-keto reductase subfamily 1c3 (akr1c3) inhibitors
NZ746691A (en) 2012-11-13 2020-08-28 Astellas Pharma Inc Agents for treatment of claudin expressing cancer diseases
MX2015011712A (es) 2013-03-06 2016-04-04 Merrimack Pharmaceuticals Inc Anticerpos biespecificos fc en fila anti-c-met.
WO2014146672A1 (en) 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2015065505A1 (en) * 2013-10-29 2015-05-07 Duke University Use of cyp27a1 inhibitors, statin, or lxr antagonists alone or in combination with conventional therapy for the treatment of breast cancer
US10975164B2 (en) 2018-02-26 2021-04-13 Emory University Antibodies useful for detection of human carcinoma antigen
US12460000B2 (en) 2018-09-07 2025-11-04 Itabmed (Hk) Limited Anti-CD19 and anti-CD3 bispecific antigen binding proteins and uses thereof
WO2020132810A1 (en) 2018-12-24 2020-07-02 Generon (Shanghai) Corporation Ltd. Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1226172A (zh) * 1996-05-31 1999-08-18 斯克里普斯研究学院 用于抑制血管发生的方法和组合物
RU2188025C2 (ru) * 2000-07-19 2002-08-27 Ростовский научно-исследовательский онкологический институт Способ лечения рака молочной железы
US20050009097A1 (en) * 2003-03-31 2005-01-13 Better Marc D. Human engineered antibodies to Ep-CAM
US20050180979A1 (en) * 2004-02-13 2005-08-18 Micromet Ag Anti-EpCAM immunoglobulins
KR101296264B1 (ko) * 2006-02-09 2013-08-14 암젠 리서치 (뮌헨) 게엠베하 전이성 유방암의 치료
RU2769948C2 (ru) * 2007-04-03 2022-04-11 Эмджен Рисерч (Мьюник) Гмбх CD3-Эпсилон-связывающий домен с межвидовой специфичностью

Similar Documents

Publication Publication Date Title
JP2013067645A5 (enExample)
Giger et al. Biomedical applications of bisphosphonates
RU2434640C2 (ru) Лечение метастатического рака молочной железы
JP2011173928A5 (enExample)
JP2014513089A5 (enExample)
NZ630790A (en) Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes
JP2012180381A5 (enExample)
JP2012067116A5 (enExample)
HK1221646A1 (zh) 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途
JP2012506448A5 (enExample)
JP2012193216A5 (enExample)
NZ606993A (en) Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
JP2016530280A5 (enExample)
PH12014502447A1 (en) Use of high dose laquinimod for treating multiple sclerosis
JP2011225596A5 (enExample)
EA201391689A1 (ru) Система доставки лекарственного средства
JP2017503014A5 (enExample)
PH12015500653A1 (en) Combination drug comprising gemigliptin and metformin, and method for the preparation thereof
JP2015507020A5 (enExample)
JP2013541587A5 (enExample)
RU2013108390A (ru) Фармацевтическая композиция для предотвращения периоперационной артериальной гипотензии у человека
RU2012108144A (ru) Противораковая терапия, направленная против раковых стволовых клеток и форм рака, устойчивых к лечению лекарственными препаратами
HRP20220701T1 (hr) Spojeni benzazepini za liječenje touretteova sindroma
JP2020512408A5 (enExample)
Sattar et al. Evaluation of the one-year efficacy, safety and glycaemic effects of evolocumab (AMG 145) in 4,802 subjects with, at high risk for, or at low risk for, diabetes mellitus